AlloVir (NASDAQ:ALVR) layoffs are in the news after the clinical-stage cell therapy company announced a massive number of job cuts. AlloVir has revealed that a new round of layoffs will have it ...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired AlloVir, Inc. (NASDAQ: ALVR ...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired AlloVir, Inc. (NASDAQ: ALVR ...

As of August 2, 2023, the average one-year price target for AlloVir is 22.10. The forecasts range from a low of 15.15 to a high of $31.50. The average price target represents an increase of 649.15% ...

Gilead has purchased $10.9 million in shares of AlloVir, a biotech company specializing in cell therapy and organ transplant, giving it a 15% ownership of the company. AlloVir's lead product, ...

Fintel reports that on August 18, 2023, B of A Securities initiated coverage of AlloVir (NASDAQ:ALVR) with a Buy recommendation. As of August 2, 2023, the average one-year price target for AlloVir is ...

AlloVir, Inc. (ALVR) is a good speculative biotech play to look into. The reason why I state that is because it has a great late-stage program, whereby it is advancing posoleucel for the treatment and ...

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS ...